Douglas J Harrison
Overview
Explore the profile of Douglas J Harrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakazawa M, Livingston J, Zarzour M, Bishop A, Ratan R, Ludwig J, et al.
Rare Tumors
. 2024 Aug;
16:20363613241271669.
PMID: 39105190
Rhabdomyosarcomas are the most common soft tissue sarcoma in children, and pediatric alveolar rhabdomyosarcoma (ARMS) prognosis has improved based on cooperative studies. However, in adults, ARMS is significantly rarer, has...
2.
Gupta A, Xue W, Harrison D, Hawkins D, Dasgupta R, Wolden S, et al.
Lancet Oncol
. 2024 Jun;
25(7):912-921.
PMID: 38936378
Background: The Children's Oncology Group defines intermediate-risk rhabdomyosarcoma as unresected FOXO1 fusion-negative disease arising at an unfavourable site or non-metastatic FOXO1 fusion-positive disease. Temsirolimus in combination with chemotherapy has shown...
3.
Metts J, Xue W, Gao Z, Oberoi S, Weiss A, Venkatramani R, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(7):e31009.
PMID: 38627882
Background: Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that...
4.
Harrison D, Qumseya A, Xue W, Arnold M, Lautz T, Hiniker S, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30847.
PMID: 38282125
Introduction: The impact of established prognostic factors on survival outcomes for childhood rhabdomyosarcoma (RMS) have not been well described in the adolescent and young adult (AYA) RMS patient population. Methods:...
5.
Weiss A, Harrison D
J Clin Oncol
. 2023 Nov;
42(6):675-685.
PMID: 37967293
Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key differences exist in the presentation...
6.
Oberoi S, Qumseya A, Xue W, Harrison D, Rudzinski E, Wolden S, et al.
Pediatr Blood Cancer
. 2023 May;
:e30436.
PMID: 37243336
Background: Temsirolimus has shown in vivo activity against rhabdomyosarcoma (RMS). We aimed to determine the feasibility of incorporating temsirolimus within the standard Children's Oncology Group (COG) chemotherapy backbone of vincristine,...
7.
Carmagnani Pestana R, Moyers J, Roszik J, Sen S, Hong D, Naing A, et al.
Clin Cancer Res
. 2023 Apr;
29(9):1708-1718.
PMID: 37058010
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in...
8.
Hingorani P, Zhang W, Zhang Z, Xu Z, Wang W, Roth M, et al.
Mol Cancer Ther
. 2022 Jun;
21(8):1318-1325.
PMID: 35657346
HER2 is expressed in many pediatric solid tumors and is a target for innovative immune therapies including CAR-T cells and antibody-drug conjugates (ADC). We evaluated the preclinical efficacy of trastuzumab...
9.
Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, et al.
Mol Cancer Ther
. 2022 Mar;
21(6):903-913.
PMID: 35312779
Immunoconjugates targeting cell-surface antigens have demonstrated clinical activity to enable regulatory approval in several solid and hematologic malignancies. We hypothesize that a rigorous and comprehensive surfaceome profiling approach to identify...
10.
Crane J, Xue W, Qumseya A, Gao Z, Arndt C, Donaldson S, et al.
Pediatr Blood Cancer
. 2022 Mar;
69(6):e29644.
PMID: 35253352
The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after...